Determination of nifeviroc, a novel CCR5 antagonist: Application to a pharmacokinetic study

被引：10

作者：

Wu, Wei ^{[1
]}

Xie, Dong ^{[1
]}

Cheng, Zeneng ^{[1
]}

Liu, Zhi ^{[2
]}

Ran, Liling ^{[2
]}

Gu, Zhenkun ^{[1
]}

Yu, Peng ^{[1
]}

机构：

[1] Cent S Univ, Sch Pharmaceut Sci, Changsha 410013, Hunan, Peoples R China

[2] Hunan Tiger Xiangya R&D Co Ltd, Changsha 410013, Hunan, Peoples R China

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2011年 / 56卷 / 03期

关键词：

Nifeviroc; CCR5; antagonist; LC-ESI-MS/MS; Pharmacokinetics; DISCOVERY; POTENT; MARAVIROC; ENTRY;

D O I：

10.1016/j.jpba.2011.06.027

中图分类号：

O65 [分析化学];

学科分类号：

070302 [分析化学];

摘要：

Nifeviroc is a novel CCR5 antagonist used for the treatment of HIV type-1 infection. A LC-ESI-MS/MS method for the determination of nifeviroc in human plasma was developed and validated. The calibration curve (r(2) =0.9993) of nifeviroc was established at the range of 1.924-2935 mu g L-1. The intra- and inter-day precisions (RSD%) were all less than 7%, and the accuracies at three concentration levels were all within 100 +/- 5%. This validated method was then successfully applied to a pharmacokinetic study in health Chinese volunteers. (C) 2011 Elsevier B.V. All rights reserved.

引用

收藏

页码：637 / 640

页数：4

相关论文

共 10 条

[1]

The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention [J].

Cascieri, MA ;

Springer, MS .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2000, 4 (04) :420-427

[2]

HIV-1 entry into CD4(+) cells is mediated by the chemokine receptor CC-CKR-5 [J].

Dragic, T ;

Litwin, V ;

Allaway, GP ;

Martin, SR ;

Huang, YX ;

Nagashima, KA ;

Cayanan, C ;

Maddon, PJ ;

Koup, RA ;

Moore, JP ;

Paxton, WA .

NATURE, 1996, 381 (6584) :667-673

[3]

Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity [J].

Imamura, S ;

Ichikawa, T ;

Nishikawa, Y ;

Kanzaki, N ;

Takashima, K ;

Niwa, S ;

Iizawa, Y ;

Baba, M ;

Sugihara, Y .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (09) :2784-2793

[4]

Kuritzkes D, 2008, NAT REV DRUG DISCOV, V7, P15, DOI 10.1038/nrd2490

[5]

Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil [J].

Guerra Corado, Andre de Lima ;

Villarouco da Silva, George Allan ;

Carvalho Leao, Renato Augusto ;

Granja, Fabiana ;

Naveca, Felipe Gomes .

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2016, 20 (03) :314-315

[6]

Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent [J].

Ma, Dawei ;

Yu, Shanghai ;

Li, Ben ;

Chen, Li ;

Chen, Renhai ;

Yu, Kunqian ;

Zhang, Linqi ;

Chen, Zhiwei ;

Zhong, Dafang ;

Gong, Zheng ;

Wang, Renxiao ;

Jiang, Hualiang ;

Pei, Gang .

CHEMMEDCHEM, 2007, 2 (02) :187-193

[7]

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-Chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro [J].

Maeda, K ;

Nakata, H ;

Koh, Y ;

Miyakawa, T ;

Ogata, H ;

Takaoka, Y ;

Shibayama, S ;

Sagawa, K ;

Fukushima, D ;

Moravek, J ;

Koyanagi, Y ;

Mitsuya, H .

JOURNAL OF VIROLOGY, 2004, 78 (16) :8654-8662

[8]

The entry of entry inhibitors: A fusion of science and medicine [J].

Moore, JP ;

Doms, RW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) :10598-10602

[9]

Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists [J].

Palani, Anandan ;

Tagat, Jayaram R. .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (10) :2851-2857

[10]

Maraviroc: a new CCR5 antagonist [J].

Sayana, Shilpa ;

Khanlou, Homayoon .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) :9-19